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Abstract
Introduction—This study examined state-level variation in chronic kidney disease (CKD) 
awareness using national estimates of disease awareness among adults in the U.S. with CKD.
Methods—Data on U.S. adults were obtained from two national, population-based surveys: (1) 
the Behavioral Risk Factor Surveillance System (BRFSS 2011; n=506,467), a state-level phone 
survey containing information on self-reported kidney disease; and (2) the National Health and 
Nutrition Examination Survey (NHANES 2005–2012; n=20,831), containing physical health 
examination, surveys containing data on self-reported kidney disease, risk factors, and laboratory 
values. CKD was defined as an estimated glomerular filtration rate of 15–59 mL/minute/1.73 m2 
or urinary albumin-to-creatinine ratio >30 mg/g. As BRFSS does not include laboratory data, 
CKD status for each person was imputed (multiple) based on a logistic regression model 
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predicting NHANES CKD status. CKD awareness in each state was estimated as the weighted 
proportion of BRFSS participants with imputed CKD who reported having kidney disease.
Results—Overall, estimated CKD awareness was 9.0% (95% CI=8.0%, 10.0%), ranging from 
5.8% (95% CI=4.8%, 6.8%) in Iowa to 11.7% (95% CI=9.7%, 13.7%) in Arizona. Awareness was 
greater among adults with hypertension (12.0%) and diabetes (15.3%) than among adults without 
those conditions, and lower in Hispanics (6.0%) than in non-Hispanic whites (8.8%), non-Hispanic 
blacks (9.9%), and other racial/ethnic groups (12.7%).
Conclusions—Among individuals with CKD, awareness of their condition was very low and 
varied approximately twofold among states. This is the first study to estimate awareness of kidney 
disease by state for the U.S. adult population.
INTRODUCTION
Chronic kidney disease (CKD) is a silent yet serious condition that often goes undetected 
until its later stages, even in high-risk subgroups, such as those with diabetes and 
hypertension.1 CKD prevalence in the adult U.S. population is estimated at about 14%; in 
certain groups, such as those aged ≥60 years, prevalence is about 25%.2–4 Morbidity and 
mortality are high among individuals with CKD, who in 2011 experienced, on average, 0.43 
hospitalizations per patient year and 140 deaths per 1,000 patient years.2 CKD is associated 
with increased mortality from cardiovascular disease5 in particular, and has moved from the 
21st (1990) to the 16th (2010) leading cause of premature death and years of life lost.6,7
Awareness of CKD is defined as the proportion of people with CKD who are aware of their 
condition. Analysis of National Health and Nutrition Examination Survey (NHANES) 
2005–2012 data demonstrated that only 7.4% of individuals in the U.S. with CKD were 
aware of their disease.8 As NHANES was not designed to yield state-specific estimates, the 
extent of geographic variation in CKD awareness is currently unknown. Knowledge of state-
specific CKD awareness could assist public health agencies in directing allocation of 
resources to areas with greatest public health need. Greater awareness of CKD and its risk 
factors could lead to reductions in mortality, morbidity, and progression to end-stage renal 
disease by increasing the likelihood of receiving timely and appropriate health care.8 As part 
of the U.S. Centers for Disease Control and Prevention’s CKD Surveillance System,9 this 
study estimated state-level awareness of CKD using cross-sectional data from two nationally 
representative surveys: NHANES and the Behavioral Risk Factor Surveillance System 
(BRFSS).
METHODS
Cross-sectional data derived from two sources were examined: The 2011 BRFSS; and 2005–
2006, 2007–2008, 2009–2010, and 2011–2012 waves of NHANES.10,11 Using logistic 
regression in a multi-year NHANES sample, CKD status for each BRFSS participant was 
multiply imputed10 based on CKD risk factors such as age, race, sex, diabetes, and 
hypertension status. CKD awareness in each state was estimated as the weighted proportion 
of BRFSS participants with imputed CKD who reported having kidney disease.12 All data 
analyses were conducted during 2014–2016.
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Study Population
The population-based NHANES samples are designed for national inference, not to produce 
state-based estimates. BRFSS is the world’s largest ongoing telephone health survey 
developed and conducted to monitor state-level prevalence of the major behavioral risks 
associated with premature morbidity and mortality in adults. The 2005–2012 NHANES data 
included information from all participants aged ≥18 years. Those who had either missing 
data for serum creatinine, were pregnant or menstruating at the time of examination, or had 
received dialysis within 12 months of the survey were excluded from analysis, leaving a 
sample of 20,831 individuals. The 2011 BRFSS survey included a total of 506,467 
individuals aged ≥ 18 years, ranging from 3,543 participants in Alaska to 25,416 in 
Nebraska. In this study, awareness was estimated for states within the continental U.S., 
Alaska, and District of Columbia, excluding data from 16,106 residents of Hawaii, Guam, 
and Puerto Rico.
Measures
Beginning in 2011, BRFSS asked all respondents: Has a doctor, nurse, or other health 
professional ever told you that you have kidney disease? Do NOT include kidney stones, 
bladder infection, or incontinence (incontinence is not being able to control urine flow.) A 
yes response was categorized as self-reported kidney disease and a no or don’t know/not 
sure response as no self-reported kidney disease. In addition to the self-report status for 
CKD, BRFSS data were utilized on self-reported age, sex, race/ethnicity, hypertension, and 
diabetes as covariates. BRFSS imputes missing race/ethnicity responses based on the 
geographic region of residence, and missing age responses as the average sample age; the 
analysis used these BRFSS-provided values.11 In BRFSS, race/ethnicity was classified as 
either non-Hispanic white, non-Hispanic black, Hispanic, Asian, Pacific Islander, or Native 
American. For the purpose of these analyses, Asian, Pacific Islander, and Native American 
were grouped with other, unknown, or more than one race choices into an “others” category. 
Hypertension and diabetes status were determined based on the responses to the questions: 
Has a doctor, nurse, or other health professional ever told you that you have diabetes? and 
Have you EVER been told by a doctor, nurse, or other health professional that you have high 
blood pressure? Respondents answering yes were categorized as having the condition 
(including women who reported having diabetes during pregnancy only) and respondents 
answering no or don’t know/not sure as not having the condition. As there were only 1,636 
(0.33%) respondents with missing information or a refused response on questions regarding 
hypertension, diabetes, or kidney disease, these respondents were excluded from analysis.
Obtained from the NHANES data set was information on age, sex, race/ethnicity, sample 
weight, and masked variance unit for each individual from the Demographic Variables and 
Sample Weights data file. Information from the urinary albumin and urinary creatinine 
components of laboratory data was used to determine CKD status. CKD was defined as 
estimated glomerular filtration rate (GFR) of 15–59 mL/minute/1.73 m2 or urinary albumin-
to-creatinine ratio >30 mg/g. Two separate analyses were conducted to estimate GFR using 
equations from the Modification of Diet in Renal Disease (MDRD) Study and the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI). The urine pregnancy test 
component of the laboratory data identified pregnant survey participants and the kidney 
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conditions– urology section of the questionnaire data files identified participants who self-
reported kidney disease, but who had received dialysis in the past 12 months. Self-reported 
kidney disease status was determined as described for BRFSS participants, using the 
NHANES question: Has a doctor, nurse, or other health professional ever told you have 
weak or failing kidneys? Do NOT include kidney stones, bladder infection, or incontinence. 
Race was classified in the BRFSS sample. Hypertension and diabetes statuses were 
determined using the same conventions described for the BRFSS: Has a doctor, nurse, or 
other health professional ever told you that you have diabetes? and Have you ever been told 
by a doctor or other health professional that you have hypertension, also called high blood 
pressure?
Statistical Analysis
Using survey sample weights, first, state-specific prevalence of self-reported kidney disease 
was estimated as the weighted proportion of survey respondents with self-reported kidney 
disease. This proportion was then stratified by age, sex, race/ethnicity, hypertension status, 
and diabetes status.
As the BRFSS sample did not contain laboratory data, CKD status was multiply imputed for 
each participant using information on the following covariates: age, sex, race/ethnicity, 
hypertension, diabetes, and self-reported kidney disease. To impute CKD status in the 
BRFSS sample, the approach detailed in Schenker et al.13 was used. In their work, Schenker 
and colleagues demonstrated the use of information from an examination-based survey such 
as NHANES to correct estimates of disease prevalence obtained from self-reported health 
data in large-scale surveys such as BRFSS. First, the BRFSS and the NHANES data were 
stacked together. Then, a logistic regression model was built relating the aforementioned 
covariates to CKD status in those individuals where CKD status was observed (i.e., in 
individuals making up the NHANES samples). From this logistic regression model the 
predicted probabilities of CKD status for individuals with a missing CKD status were 
obtained (i.e., individuals in the BRFSS sample). The missing CKD status was imputed 
using these predicted probabilities. A detailed step-by-step explanation of the imputation 
procedure is provided in the Appendix (available online). Using IVEware, version 0.2 
(www.isr.umich.edu/src/smp/ive/), ten imputations of CKD status were created for each 
participant in the BRFSS sample. As two different definitions of CKD based on two 
different estimated GFR equations (CKD-EPI and MDRD) were used, the imputations were 
carried out twice—once for each CKD definition.
Finally, the awareness of CKD(Aim) in state i and imputation m was estimated as the 
weighted proportion of BRFSS participants with imputed CKD who self-reported kidney 
disease in state i. Estimates from the different imputations were combined using the standard 
rules for combining estimates from multiply imputed data sets.14
RESULTS
In 2011 BRFSS data, 2.5% (95% CI=2.4%, 2.6%) of the U.S. population reported having 
been told they have kidney disease. A lower proportion of 2005–2012 NHANES participants 
reported weak or failing kidneys (1.9%, 95% CI=1.7%, 2.2%). In both samples, self-
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reported kidney disease was highest among adults with diabetes or hypertension and among 
those aged ≥65 years.
Based on the imputation method applied to the BRFSS sample to project GFR, the 
prevalence of CKD in the U.S. was estimated to be 14.5% (95% CI=13.9%, 15.1%) using 
the CKD-EPI equation, and 15.6% (95% CI=15.1%, 16.2%) using the MDRD equation 
(Table 1). Estimated CKD prevalence was highest among adults with diabetes or 
hypertension and those aged ≥65 years. Direct estimates of CKD prevalence based on 
laboratory data in the 2011–2012 NHANES sample were 1.2% lower than those obtained 
using a multiple imputation method in the BRFSS sample (Table 1).
Awareness of CKD in the U.S. using BRFSS data was estimated at 9.0% (95% CI=8.0%, 
10.0%) using the CKD-EPI equation and 8.6% (95% CI=7.7%, 9.5%) using the MDRD 
equation to estimate GFR (Table 2). From the 2011–2012 NHANES sample containing both 
survey data (asking about “weak or failing kidneys”) and laboratory data, overall CKD 
awareness was estimated at 9.1% (95% CI=6.2%, 11.9%; CKD-EPI) and 8.5% (95% 
CI=5.8%. 11.1%; MDRD). Thus, the multiple imputation method yielded estimates of CKD 
awareness that were similar to the design-based estimates in NHANES, but with potentially 
greater precision, owing to the larger sample size in BRFSS.
When examining covariate categories, use of CKD-EPI and MDRD equations yielded 
similar estimates of CKD awareness among imputed CKD cases in BRFSS. Awareness was 
higher among adults with hypertension (12.0%, CKD-EPI; 11.6%, MDRD) and among those 
with diabetes (15.3% and 14.7%) compared with those without these conditions. Awareness 
was lower in Hispanics (6.0% and 5.9%) than in other racial/ethnic groups (Table 3).
Within the continental U.S., Alaska, and the District of Columbia, the state-specific 
proportion of self-reported kidney disease ranged from 1.5% in Iowa to 3.5% in Arizona 
(Figure 1, Plot A; Table 3). Other states with the highest proportions of self-reported kidney 
disease were (in decreasing order) Florida, Oklahoma, New Mexico, and Michigan. The 
estimated state-specific prevalence of imputed CKD ranged from 11.6% in Utah to 16.7% in 
Florida, using the CKD-EPI equation (Figure 1, Plot B; Table 3), and from 12.7% in Utah to 
17.8% in Florida using the MDRD equation (results not shown). State-specific awareness of 
CKD among imputed cases ranged from 5.8% in Iowa to 11.7% in Arizona (CKD-EPI; 
Figure 1, Plot C; Table 3) and from 5.4% in Iowa to 11.1% in Arizona (MDRD; results not 
shown). Using either equation to estimate GFR, states with the highest levels of CKD 
awareness were Arizona, New Mexico, Georgia, the District of Columbia, and West 
Virginia; states with the lowest levels of awareness were Iowa, New Jersey, Minnesota, 
Maryland, and Massachusetts (Figure 1, Plot C; Table 3).
DISCUSSION
To the authors’ knowledge, this work represents the first attempt to examine geographic 
variation in CKD awareness in the general U.S. population. Estimates from two large U.S. 
population-based surveys revealed that adult awareness of CKD in the general population is 
very low. Though variation in the degree of awareness by state was observed, even among 
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states with relatively higher awareness, <13% of the general population that has kidney 
disease was estimated to be aware of their CKD. Any attempt to estimate population 
awareness of CKD requires identification of those affected. As the data sources did not 
contain both laboratory data and geographic location information for the same set of 
individuals, an indirect approach was utilized to estimate both state-level prevalence and 
awareness of CKD by developing a predictive regression model in a sample with laboratory 
and clinical data (NHANES), followed by multiple imputation in a population sample with 
self-reported, but no clinical/laboratory data (BRFSS).
Estimated awareness of CKD was found to vary about twofold among states in 2011. 
Further, the ranking of states with respect to estimated CKD awareness differed from the 
ranking of self-reported kidney disease. For example, although Georgia ranked as one of the 
five most aware states by the imputation method, it ranked 11th in the country with respect 
to self-reported kidney disease in BRFSS. Such discrepancies perhaps suggest differences in 
awareness and testing levels among states. Indeed, assuming that the imputation method 
leads to accurate estimates of state-level prevalence, the rate of self-report observed in 
Georgia is higher than what would be expected for a state with the corresponding 
prevalence. This indicates a higher rate of awareness in the state, perhaps driven by higher 
testing levels and greater access to care.
Using the BRFSS data imputation, overall awareness of CKD in the U.S. was estimated to 
be 9%. This estimate seems consistent with that reported by previous investigators using 
data from volunteer participants in the National Kidney Foundation’s Kidney Early 
Evaluation Program15–17 and those using NHANES data, with awareness estimates between 
6.0% and 9.0%.18,19
In BRFSS 2011, the estimated awareness of CKD was higher in men than women, and in 
adults with diabetes or hypertension versus those without these comorbid conditions. These 
results were consistent with results from a previous study based on NHANES data.18 The 
use of NHANES 2011–2012 data led to estimates of CKD awareness that were similarly 
higher in the hypertensive and diabetic subgroups, but lower in men than in women. 
However, the lack of precision in these estimates, based on a single wave of NHANES data, 
limits the interpretation of subgroup comparisons. The approach produced more-precise 
estimates of the burden of CKD in the general population. This gain in precision comes 
without an additional data collection burden, as the method leverages existing data from 
publicly available data sources, such as NHANES and BRFSS.
As expected, the choice of equation used to estimate GFR influenced the overall estimate of 
imputed CKD prevalence in the U.S. (14.5% by CKD-EPI equation vs 15.6% by MDRD 
equation), although this made less of a difference in estimating overall awareness in the U.S. 
(9.0% CKD-EPI vs 8.6% MDRD) and awareness within risk factor categories. Consistency 
in estimating awareness is a desirable property of any method with a potential use in 
surveillance programs.
It should be noted that the questions pertaining to kidney disease in NHANES and BRFSS 
are worded differently. Whereas the BRFSS question asks Ever told you have kidney 
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disease?, the NHANES question asks Ever told you have weak or failing kidneys? This 
semantic difference may have affected the responses of participants, with 2.5% of 
participants in the BRFSS sample answering yes compared with 1.9% of NHANES 
participants. As self-reported information was used to multiply impute CKD status for 
BRFSS participants, prevalence estimates were 1.2% higher than the corresponding direct 
estimates obtained using 2011–2012 NHANES data (Table 2). However, the difference in 
question wording seemed to have no effect on estimates of CKD awareness. In fact, 
estimates based on the imputation method were nearly identical to the direct estimates based 
on 2011–2012 NHANES data, with the added advantage of being more precise (Table 2).
Limitations
The main limitations of this study are the assumptions involved in the estimation of CKD 
awareness. Although the authors’ method produces estimates with improved precision 
compared with direct survey-based estimates from NHANES, as with any imputation-based 
quantity, these estimates may be biased if the underlying imputation model is incorrect. A 
gain in precision, however, does not equate to a gain in accuracy. In building a model to 
predict CKD using NHANES data, it was assumed that the NHANES assessment of CKD 
was accurate and that the authors’ model predicting CKD status was properly specified and 
did not exclude any important predictors of CKD. Further, it was assumed that CKD status 
in BRFSS participants was missing at random; that is, it was assumed that given the 
covariates used in the model, the missing data or lack of information on CKD status for 
BRFSS participants did not depend on the actual CKD status of these individuals and could 
be derived from the available information on covariates.
Although the two survey samples were probability samples of the U.S. population, they may 
represent slightly different source populations. For example, BRFSS is a telephone survey 
but NHANES is not, and though participants in both surveys were asked similar interview 
questions, participants in the NHANES are given laboratory tests following their interview, 
which may influence their answers. Thus, a single “global” regression model built using all 
the NHANES data may not capture the true relation between clinical CKD and its risk 
factors for all participants in the BRFSS sample. This raises concerns about the portability of 
the imputation model, that is, whether the model fitted to the NHANES data can be applied 
to the BRFSS data to predict clinical disease status. This concern is addressed in the 
imputation approach by fitting separate “local” imputation models in different regions of the 
covariate space; that is, the combined data of NHANES and BRFSS samples were divided 
into subgroups for which the distributions of the covariates were similar across the two 
surveys, and then the imputations were carried through separate regression models fitted 
within each subgroup.
CONCLUSIONS
The results suggest that among adults with CKD, awareness of the condition is very low and 
varies about twofold among U.S. states. This appears to be the first report that provides an 
efficient method to estimate both CKD prevalence and CKD awareness at the state level 
without an additional data collection burden, leveraging existing data from two large, 
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probability samples of the U.S. population: NHANES and BRFSS. The study presents a 
quantitative approach to indirectly estimate the awareness of CKD among individuals with 
the condition at the state level in the absence of laboratory information on patient CKD 
status. This approach could be applied to CKD surveillance programs to study geographic 
variation and trends in CKD awareness across the U.S. and to understand factors underlying 
those variations. Future research should focus on validating (by state-level data collection) 
and examining CKD awareness at even more geographically granular levels.
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Figure 1. 
Mean and 95% CI of self-reported CKD in the BRFSS (Plot A), imputed prevalence of CKD 
(Plot B) and estimated CKD awareness among imputed cases (Plot C), by state, using CKD-
EPI equation to estimate GFR.
CKD, chronic kidney disease; BRFSS, Behavioral Risk Factor Surveillance System; CKD-
EPI, CKD Chronic Kidney Disease Epidemiology Collaboration Equation; GFR, glomerular 
filtration rate.
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Table 1
Estimated U.S. CKD Prevalence Using NHANES and BRFSS, by Equation Estimating GFR and Covariate 
Category
GFR estimate MDRD equation GFR estimate CKD-EPI equation
Characteristics
NHANES 2011–2012
(n=5,055)
Imputed BRFSS 2011
(n=506,467)
NHANES 2011–2012
(n=5,055)
Imputed BRFSS 2011
(n=506,467)
Overall 14.4 (12.5, 16.3) 15.6 (15.1, 16.2) 13.3 (11.6, 15.1) 14.5 (13.9, 15.1)
Age, years
  <65 8.4 (6.8, 10.0) 10.0 (9.5, 10.6) 8.4 (6.8, 10.0) 8.9 (8.4, 9.5)
  ≥65 37.6 (35.1, 40.1) 41.5 (39.7, 43.2) 37.6 (35.1, 40.1) 40.4 (38.5, 42.3)
Race
  Non-Hispanic white 13.1 (10.9, 15.3) 15.8 (15.1, 16.4) 13.1 (10.9, 15.3) 14.4 (13.7, 15.1)
  Non-Hispanic black 16.9 (14.7, 19.1) 16.1 (15.2, 17.0) 16.9 (14.7, 19.1) 16.4 (15.4, 17.4)
  Hispanic 12.5 (9.2, 15.8) 12.8 (10.7, 14.9) 12.5 (9.2, 15.8) 12.4 (10.3, 14.4)
  Others 12.4 (8.7, 16.0) 14.0 (11.9, 16.1) 12.4 (8.7, 16.0) 13.5 (11.4, 15.7)
Sex
  Male 12.2 (9.6, 14.7) 12.8 (11.8, 13.7) 12.2 (9.6, 14.7) 12.4 (11.4, 13.5)
  Female 14.5 (12.8, 16.2) 18.3 (17.9, 18.7) 14.5 (12.8, 16.2) 16.5 (16.0, 17.0)
Diabetes
  No 10.7 (9.2, 12.2) 12.7 (12.2, 13.2) 10.7 (9.2, 12.2) 11.7 (11.1, 12.2)
  Yes 35.7 (30.5, 40.9) 39.5 (37.4, 41.5) 35.7 (30.5, 40.9) 37.9 (35.8, 40.1)
Hypertension
  No 8.1 (6.5, 9.7) 9.5 (8.9, 10.1) 8.1 (6.5, 9.7) 8.6 (8.0, 9.2)
  Yes 25.2 (22.7, 27.8) 28.3 (27.1, 29.4) 25.2 (22.7, 27.8) 26.7 (25.4, 27.9)
Note: Values are % (95% CI). Appropriate survey weights were used in all calculations to account for complex sample design features in each 
survey.
BRFSS, Behavioral Risk Factor Surveillance System; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology 
Collaboration Equation; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease Study Equation; NHANES, National 
Health and Nutrition Examination Survey.
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Table 2
Estimated U.S. CKD Awareness Using NHANES and BRFSS, by Equation Estimating GFR and Covariate 
Category
GFR estimate MDRD equation GFR estimate CKD-EPI equation
Characteristics
NHANES 2011–2012
(n=5,055)
Imputed BRFSS 2011
(n=506,467)
NHANES 2011–2012
(n=5,055)
Imputed BRFSS 2011
(n=506,467)
Overall 8.5 (5.8, 11.1) 8.6 (7.7, 9.5) 9.1 (6.2, 11.9) 9.0 (8.0, 10.0)
Age, years
  <65 7.8 (4.5, 11.2) 7.9 (6.8, 9.1) 8.8 (5.3, 12.4) 8.5 (7.3, 9.9)
  ≥65 9.2 (5.2, 13.3) 9.3 (8.5, 10.1) 9.3 (5.1, 13.6) 9.5 (8.7, 10.2)
Race
  Non-Hispanic white 8.1 (4.2, 11.9) 8.4 (7.3, 9.4) 9.0 (4.7, 13.2) 8.8 (7.6, 10.1)
  Non-Hispanic black 10.8 (6.3, 15.4) 9.9 (8.5, 11.3) 10.3 (6.2, 14.4) 9.9 (8.6, 11.2)
  Hispanic 10.1 (4.1, 16.1) 5.9 (3.7, 8.1) 10.4 (4.3, 16.5) 6.0 (3.5, 8.5)
  Others 4.8 (1.2, 8.4) 12.4 (10.5, 14.3) 4.8 (1.1, 8.5) 12.7 (10.7, 14.6)
Sex
  Male 6.0 (3.1, 9.0) 9.6 (8.6, 10.7) 6.3 (3.3, 9.2) 10.0 (8.9, 11.1)
  Female 10.3 (6.5, 14.2) 7.9 (6.8, 9.0) 11.4 (7.2, 15.6) 8.3 (7.0, 9.5)
Diabetes
  No 6.6 (4.1, 9.0) 6.3 (5.2, 7.3) 7.2 (4.6, 9.7) 6.5 (5.3, 7.7)
  Yes 13.7 (8.9, 18.6) 14.7 (12.9, 16.5) 13.8 (8.9, 18.8) 15.3 (13.2, 17.4)
Hypertension
  No 5.1 (1.8, 8.3) 4.3 (3.3, 5.2) 5.5 (2.0, 9.0) 4.4 (3.3, 5.6)
  Yes 11.0 (7.6, 14.5) 11.6 (10.4, 12.7) 11.6 (8.2, 15.1) 12.0 (10.8, 13.3)
Note Values are % (95% CI). Appropriate survey weights were used in all calculations to account for complex sample design features in each 
survey.
BRFSS, Behavioral Risk Factor Surveillance System; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology 
Collaboration Equation; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease Study Equation; NHANES, National 
Health and Nutrition Examination Survey.
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